Clinical trials: HCM - Hypertrophic Cardiomyopathy
Anesthesia, Transapical Beating-heart Septal Myectomy
Anesthetic Management for TA-BSM in HOCM
To retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing TA-BSM in the investigators' hospital, and to provide clinical basis for…
- Conditions
- Anesthesia, Transapical Beating-heart Septal Myectomy, Hypertrophic Cardiomyopathy
- Trial name
- NCT06397092
- Testing
- transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Hypertrophic Cardiomyopathy Without Obstruction
Exercise Prescription in Children With Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is an inherited cardiac condition that affects the heart muscle of adults and children. Historically, doctors have been cautious about encouraging patients with HCM to exercise, as they were…
- Trial name
- Empower (NCT07595354)
- Testing
- Exercise Prescription
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Alder Hey Children's NHS Foundation Trust
Atrial Fibrillation, Hypertrophic Cardiomyopathy
HCM-AF Ablation With ACUTUS
BACKGROUND About 1/4 of patients with hypertrophic cardiomyopathy (HCM) seem to develop atrial fibrillation (AF) over their life-span.
- Trial name
- NCT04090437
- Testing
- Catheter ablation procedure
- Volunteers
- 20 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Hypertrophic Cardiomyopathy
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
Hypertrophic obstructive cardiomyopathy (HOCM) patients often develop disabling symptoms of heart failure. Current treatment strategies are predicated on the empirical use of long-standing drugs, such as beta-adrenergics…
- Trial name
- TEMPO (NCT03532802)
- Testing
- Metoprolol Succinate
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Steen Hvitfeldt Poulsen
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy
This multicenter, randomized, open-label, parallel-group, non-inferiority trial will evaluate whether sequential tapering and discontinuation of beta-blockers is non-inferior to maintenance of the baseline stable beta-blocker…
- Trial name
- STEP-oHCM (NCT07815301)
- Testing
- Beta-Blocker Sequential Tapering and Discontinuation, Beta-Blocker Baseline Stable-Dose Maintenance
- Where
- China
- Volunteers
- 286 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70…
- Trial name
- PIONEER-HCM (NCT02842242)
- Testing
- MYK-461
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- MyoKardia, Inc.
Cardiomyopathy
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality…
- Trial name
- MyCLIMB (NCT05112237)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Tenaya Therapeutics
Hypertrophic Cardiomyopathy, Long QT Syndrome
Exercise in Genetic Cardiovascular Conditions
The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS).
- Trial name
- LIVE-HCM/LQT (NCT02549664)
- Where
- 36 sites in United States, Australia and 3 more
- Volunteers
- 4,299 people
- Sponsor
- Yale University
Hypertrophic Cardiomyopathy
Echocardiography-guided Percutaneous Septal Radiofrequency Ablation for Obstructive HCM After Alcohol Septal Ablation
After alcohol ablation, some HOCM patients have serious clinical symptoms and adverse complications, and need to undergo invasive surgery again when adequate drug therapy is not effective or cannot tolerate the side effects of…
- Trial name
- HCM (NCT06496633)
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xijing Hospital
Hypertrophic Cardiomyopathy
Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain.
- Trial name
- METAL-HCM (NCT00500552)
- Where
- 3 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- University Hospital Birmingham
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Trial name
- NCT00001878
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious. Cardiomyopathy in children can result in death, disability, heart transplantation or serious heart rhythm disorders.
- Trial name
- NCT01873976
- Where
- 13 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- Wayne State University
Peripheral Artery Disease, Coronary Disease
Evaluation of Patients With Known or Suspected Heart Disease
In this study researchers will admit and evaluate patients with known or suspected heart disease referred to the Cardiology Branch of the National Heart, Lung, and Blood Institute (NHLBI).
- Conditions
- Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT00001313
- Where
- 2 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy
Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
The aim of this randomized trial is to compare the improvement in exercise capacity among patients with highly symptomatic hypertrophic obstructive cardiomyopathy despite optimal medical treatment who undergo alcohol septal…
- Trial name
- AMARONE (NCT04684290)
- Testing
- Alcohol Septal Ablation, Surgical Septal Myectomy
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- St. Antonius Hospital
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)
Hypertrophic Obstructive Cardiomyopathy (HOCM) is an inherited cardiac condition which causes the heart muscle to become abnormally thick causing obstruction of blood flow in the heart.
- Trial name
- EMORI-HCM (NCT05257772)
- Testing
- AV Delay Optimised RV Pacing
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Fabry Disease
FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation
In Fabry disease (FD) and hypertrophic cardiomyopathy (HCM) systemic inflammation recently gained attention as a possible key pathophysiologic process involved in the development of cardiac hypertrophy and progression of the…
- Trial name
- FASHION (NCT05761834)
- Testing
- Sample blood and 2D-echocardiography with Doppler
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Obstructive Hypertrophic Cardiomyopathy
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic…
- Trial name
- DISCOVER-HCM (NCT05489705)
- Testing
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Where
- 101 sites in United States, Austria and 7 more
- Volunteers
- 1,700 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Paced Dyssynchrony and Myocardial Perfusion IN apiCal Hcm
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. A relatively common subgroup of HCM patients have apical HCM - a type of heart muscle disease that causes abnormal muscle thickening towards the tip…
- Trial name
- PINCHcm (NCT04231032)
- Testing
- Asynchronous dual chamber pacing (DOO) with paced ventricular activation, Asynchronous atrial pacing (AOO) with intrinsic ventricular activation
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Barts & The London NHS Trust
Obesity, Hypertrophic Cardiomyopathy
Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy
In this study, the investigators evaluated the association between various measures of adiposity [BMI and waist circumference (WC)] and clinical outcomes in Asian patients with hypertrophic cardiomyopathy, using a nationwide…
- Conditions
- Obesity, Hypertrophic Cardiomyopathy, Cardiovascular Morbidity
- Trial name
- Paradox (NCT05645939)
- Testing
- Diasgnosis of hypertrophic cardiomyopathy
- Where
- South Korea
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Atrial Fibrillation, Hypertrophic Cardiomyopathy
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients with hypertrophic cardiomyopathy (HCM) and represents an important complication in the clinical course of the disease, with adverse…
- Trial name
- NCT00821353
- Testing
- RF catheter ablation, Antiarrhythmic drugs
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland